Meta-analysis for bioequivalence review.
The problem of drug interchangeability among a brand-name drug and its generic copies is considered. Under current Food and Drug Administration (FDA) regulation, a patient may switch from the brand-name drug to a generic drug if the generic drug is shown to be bioequivalent to the brand-name drug based on bioequivalence testing. After the patent of a brand-name drug is expired, usually there will be a number of generic copies available on the market. The FDA does not indicate that a patient may switch from a generic to another even though both of the generic drugs are bioequivalent to the brand-name drug. As a result, drug interchangeability among the brand-name and its generic copies is a safety concern. In this paper, we propose to perform a meta-analysis for an overview of bioequivalence. The proposed meta-analysis provides an assessment of bioequivalence among generic copies of a brand-name that can be used as a tool to monitor the performance of the approved generic copies of the brand-name drug. In addition, it provides more accurate estimates of inter- and intrasubject variabilities of the drug product.
Chow
S C
SC
Biostatistics and Data Management, Bristol-Myers Squibb Company, Plainsboro, New Jersey 08535, USA.
Liu
J
J
D006801:Humans; D007206:Individuality; D008432:Mathematical Computing; D015201:Meta-Analysis as Topic; D008954:Models, Biological; D013223:Statistics as Topic / Q000379:methods*; D013810:Therapeutic Equivalency